Skip to main content
OpenTrials
Completed

NCT Number: NCT04849169

Investigation of the Ringer Perfusion Balloon Catheter

The objective of this study is to demonstrate reasonable assurance that the Ringer catheter can be safely used to manage hemorrhage due to coronary vessel perforations while facilitating distal perfusion under the conditions of use prescribed in the labeling.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Emory Heart & Vascular Center, Atlanta, Georgia, United States

Loading trial locations.

About this study

A prospective, multicenter, single-arm clinical study. The study will be conducted at up to 15 investigational sites in the US and will enroll up to 30 participants. The population for this investigation is adult participants who suffer a perforation of the coronary artery during a percutaneous coronary intervention requiring management of hemorrhage while providing distal perfusion until definite treatment is determined.

This clinical investigation is being conducted under Exception from Informed Consent (EFIC) regulations because there is no reasonable way to identify patients likely to become eligible for the investigation, and a coronary perforation can be a life-threatening emergency that needs to be immediately controlled without enough time for the patient or their legally authorized representative to give consent. Patients will be notified of their enrollment as soon as feasible. For more information on the exception from informed consent, please use the contact information be.ow.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • At least 18 years of age at the time of the PCI procedure
  • Subject has fluoroscopically confirmed vessel perforation (classified as any type) requiring management of hemorrhage until a definitive treatment is determined
  • Female subjects of childbearing potential must have a negative pregnancy test per standard of care for PCI

Exclusion criteria

-The perforation location prevents complete inflation or proper placement of the Ringer catheter, as detailed in the Instructions for Use (IFU).

Treatment and study plan

Experimental

Device

Prolonged balloon inflation for hemorrhage management due to coronary artery perforation.

Primary outcomes

  1. Effectiveness of device success in managing hemorrhage while preserving flow

    Time frame: Procedure

    Effectiveness of device success in managing hemorrhage while preserving flow via angiographic confirmation of: a) successful delivery of Ringer across perforation, b) acute cessation of extravasation while Ringer is inflated, and c) demonstration of antegrade blood flow during Ringer deployment.

  2. Rate of Ringer related thrombosis and/or dissection

    Time frame: Procedure

    Rate of Ringer-related thrombosis and new or worsening coronary dissection following Ringer deflation and withdrawal.

Secondary outcomes

  1. Change in TIMI (thrombolysis in myocardial infarction) flow

    Time frame: Procedure

    The change in TIMI flow during Ringer deployment.

  2. Change in perforation classification

    Time frame: Procedure

    The change in perforation classification after Ringer deployment

  3. Rate of clinically relevant events

    Time frame: Discharge or 30 days, whichever comes first.

    Rate of clinically relevant events in the management of the coronary perforation and any potential sequelae including: chest pain, bleeding incidence and severity, major adverse cardiac events (MACE), cardiac tamponade and pericardiocentesis, emergency surgery post-perforation including coronary artery bypass graft (CABG), death.

Sponsors and collaborators

Lead sponsor

Vascular Solutions LLC

Industry

Registry information

Official study title

A Prospective, Multicenter, Single-arm Investigation of the Ringer Perfusion Balloon Catheter Performed Under an Exception From Informed Consent (EFIC) (Ringer IDE Study)

Important dates

Study start
2022
Primary completion
2023
Study completion
2023
First posted
Apr 19, 2021
Registry last updated
Dec 22, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.